MATERIALSAND METHODS Antibody Preparation and Radioiodinatlon MN-l4 (Immu-14;
Immunomedics, Inc., Morris Plains, NJ) was purified by protein-A and ion-exchange …

BACKGROUND Monoclonal antibodies (MAbs) against carcinoembryonic antigen (CEA)
have been recognized as targeting agents for medullary thyroid carcinoma (MTC). This …

The targeting potential of 131I-labeled NP-4 and MN-14 anti-CEA (carcinoembryonic
antigen) monoclonal antibodies (MAbs) was assessed in 19 patients with metastatic …

We have shown previously significant antitumor effects using 90Y-MN-14 anti-CEA
monoclonal antibody (MAb) for radioimmunotherapy (RAIT) of human medullary thyroid …

The poor prognosis of patients with advanced medullary thyroid carcinoma (MTC) has
prompted a search for new treatment modalities. In this report we explore the characteristics …

The toxicity and therapeutic efficacy of escalating doses of anti-carcinoembryonic antigen×
anti-Nα-(diethylenetriamine-N, N, N′, N ″-tetraacetic acid)-In bispecific monoclonal …

Whereas in advanced metastatic medullary thyroid cancer (MTC), a variety of
chemotherapeutic regimens have achieved only limited success clinically, more recently …

This study compared the toxicity and efficacy of 131I-labeled bivalent hapten pretargeted by
anti-carcinoembryonic antigen (CEA)/anti-Nα-(diethylenetriamine-N, N, N′, N ″-tetraacetic …

Radioimmunotherapy of Medullary Thyroid Cancer with Iodine-131-Labeled Anti-CEA
Antibodies Page 1 Radioimmunotherapy of Medullary Thyroid Cancer with Iodine-131-Labeled …

This trial determined the pharmacokinetics, dosimetry, and dose-limiting toxicity of 90Y-hMN-
14 IgG (humanized anticarcinoembryonic antigen [CEA, or CEACAM5] monoclonal …